Vemurafenib

Generic Name: Vemurafenib

Brand Names: Zelboraf

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₈ClF_₂N_₃O_₃S

CAS Number: 918504-65-1

Unique Ingredient Identifier: 207SMY3FQT

Background: Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication: Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions: Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease

Associated Therapies: -

Clinical Trials

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Vemurafenib
Drug: Cetuximab

First Posted Date: 2018-11-01

Last Posted Date: 2021-08-19

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 30

Registration Number: NCT03727763

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Cobimetinib
Drug: Atezolizumab
Drug: Vemurafenib

First Posted Date: 2018-08-10

Last Posted Date: 2024-04-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT03625141

Locations: 🇧🇷
Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil
🇧🇷
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, RS, Brazil
🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil

and more 19 locations

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

Phase 2

Recruiting

Conditions: Langerhans Cell Histiocytosis

Interventions: Drug: Vemurafenib
Drug: Cytarabine
Drug: 2-chlorodeoxyadenosine

First Posted Date: 2018-07-13

Last Posted Date: 2023-03-16

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 12

Registration Number: NCT03585686

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Phase 2

Active, not recruiting

Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Interventions: Drug: Atezolizumab
Biological: Tiragolumab
Drug: Cobimetinib
Drug: Vemurafenib

First Posted Date: 2018-06-12

Last Posted Date: 2024-11-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 59

Registration Number: NCT03554083

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Phase 2

Active, not recruiting

Conditions: Cancer of Unknown Primary Site

Interventions: Drug: Alectinib
Drug: Vismodegib
Drug: Ipatasertib
Drug: Carboplatin
Drug: Olaparib
Drug: Erlotinib
Drug: Cisplatin
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Vemurafenib
Drug: Cobimetinib
Drug: Trastuzumab Subcutaneous (SC)
Drug: Pertuzumab
Drug: Atezolizumab
Drug: Paclitaxel
Drug: Entrectinib
Drug: Ivosidenib
Drug: Pemigatinib

First Posted Date: 2018-04-13

Last Posted Date: 2024-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 528

Registration Number: NCT03498521

Locations: 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮
Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland

and more 134 locations

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Phase 2

Terminated

Conditions: Malignant Melanoma Stage IV
BRAF V600 Mutation
Brain Metastases

Interventions: Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2018-02-13

Last Posted Date: 2023-09-14

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 20

Registration Number: NCT03430947

Locations: 🇩🇪
Technische Universität Dresden, Dresden, Germany
🇩🇪
Ruprecht-Karls-University of Heidelberg, Faculty of Medicine, Heidelberg, Germany
🇩🇪
Eberhard Karls University of Tübingen, University Medical Center, Tuebingen, Germany

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2

Active, not recruiting

Conditions: Hairy Cell Leukemia
Leukemia
Leukemia, Hairy Cell

Interventions: Drug: Vemurafenib
Drug: Obinutuzumab

First Posted Date: 2018-01-25

Last Posted Date: 2024-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03410875

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2

Conditions: Rare Tumor
Refractory Tumor

Interventions: Drug: Gefitinib
Drug: Erlotinib
Drug: Afatinib
Drug: Trastuzumab
Drug: Oxazolidine
Drug: Olaparib
Drug: Everolimus
Drug: Cabozantinib
Drug: Vemurafenib
Drug: Dabrafenib
Drug: Palbociclib
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent

First Posted Date: 2017-08-03

Last Posted Date: 2022-03-04

Lead Sponsor: Baodong Qin

Target Recruit Count: 300

Registration Number: NCT03239015

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2

Active, not recruiting

Conditions: BRAF V600E Mutation Present
Papillary Craniopharyngioma

Interventions: Drug: Vemurafenib
Drug: Cobimetinib
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment

First Posted Date: 2017-07-21

Last Posted Date: 2024-05-23

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 24

Registration Number: NCT03224767

Locations: 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Sutter Roseville Medical Center, Roseville, California, United States
🇺🇸
Eden Hospital Medical Center, Castro Valley, California, United States

and more 103 locations

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

Phase 2

Terminated

Conditions: Melanoma
Melanoma (Skin)
Melanoma Stage

Interventions: Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2017-07-21

Last Posted Date: 2021-04-26

Lead Sponsor: Fondazione Melanoma Onlus

Target Recruit Count: 9

Registration Number: NCT03224208

Locations: 🇮🇹
Fondazione G.Pascale, Napoli, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy